高敏肌钙蛋白与心肌梗死后的结局
该全国性队列研究纳入2009至2013年瑞典国家患者登记中87,879例首次心肌梗死患者,比较采用高敏肌钙蛋白T(hs-cTnT)与传统肌钙蛋白(cTn)诊断的患者在发病率、预后及冠脉造影和血运重建使用上的差异。结果显示hs-cTnT引入后心梗发病率增加5%,全因死亡风险无差异,再发心梗风险降低11%,而冠脉造影和血运重建使用增加。
要点
- hs-cTnT引入后心梗发病率增加5%(95%CI 0%至10%)。
- hs-cTnT诊断患者全因死亡风险无差异(调整HR 1.00;95%CI 0.97至1.02)。
- hs-cTnT诊断患者再发心梗风险降低11%(调整HR 0.89;95%CI 0.86至0.91),冠脉造影和血运重建增加。
核心结论
- hs-cTnT引入与心梗发病率增加相关,但对生存无影响。
- hs-cTnT诊断患者再发心梗风险降低,同时冠脉造影和血运重建使用增加。
研究设计与样本
- 全国性队列研究,纳入瑞典国家患者登记2009至2013年所有首次心梗患者。
- 共87,879例首次心梗患者,其中47,133例使用cTn诊断,40,746例使用hs-cTnT诊断。
- 采用Cox回归计算全因死亡、再发心梗、冠脉造影和血运重建的风险比(HR)及95%置信区间(CI)。
主要发现
- hs-cTnT引入后心梗发病率增加5%(95%CI 0%至10%)。
- 随访3.9±2.8年期间共33,492例死亡,全因死亡风险无差异(调整HR 1.00;95%CI 0.97至1.02)。
- 随访3.1±2.3年期间共15,766例再发心梗,hs-cTnT组再发心梗风险降低11%(调整HR 0.89;95%CI 0.86至0.91)。
- hs-cTnT组冠脉造影使用增加(调整HR 1.16;95%CI 1.14至1.18),血运重建增加(调整HR 1.13;95%CI 1.11至1.15)。
临床怎么用
- hs-cTnT诊断心梗后应关注再发心梗风险降低及冠脉造影和血运重建使用增加的趋势。
- hs-cTnT引入可能提高心梗检出率,但需结合临床评估避免过度诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains unknown how the introduction of high-sensitivity cardiac troponin T (hs-cTnT) has affected the incidence, prognosis, and use of coronary angiographies and revascularizations in patients with myocardial infarction (MI). OBJECTIVES: The aim of this study was to investigate how the incidence of MI and prognosis after a first MI was affected by the introduction of hs-cTnT. METHODS: In a cohort study, the authors included all patients with a first MI from the Swedish National Patient Registry from 2009 to 2013. Cox regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for risk of all-cause mortality, reinfarction, coronary angiographies, and revascularizations in patients with MI diagnosed using hs-cTnT compared with those diagnosed using conventional troponins (cTn). RESULTS: During the study period, 47,133 MIs were diagnosed using cTn and 40,746 using hs-cTnT. The rate of MI increased by 5% (95% CI: 0% to 10%) after the introduction of hs-cTnT. During 3.9 ± 2.8 years of follow-up, there were 33,492 deaths, with no difference in the risk of all-cause mortality (adjusted HR: 1.00; 95% CI: 0.97 to 1.02). There were, in total, 15,766 reinfarctions during 3.1 ± 2.3 years of follow-up, with the risk of reinfarction reduced by 11% in patients diagnosed using hs-cTnT (adjusted HR: 0.89; 95% CI: 0.86 to 0.91). The use of coronary angiographies (adjusted HR: 1.16; 95% CI: 1.14 to 1.18) and revascularizations (adjusted HR: 1.13; 95% CI: 1.11 to 1.15) increased in the hs-cTnT group. CONCLUSIONS: In a nationwide cohort study including 87,879 patients with a first MI, the introduction of hs-cTnT was associated with an increased incidence of MI, although with no impact on survival. We also found a reduced risk of reinfarction alongside increased use of coronary angiographies and revascularizations.
引用
- Odqvist M, Andersson PO, Tygesen H, et al. High-Sensitivity Troponins and Outcomes After Myocardial Infarction. J Am Coll Cardiol. 2018. PMID: 29880121. doi:10.1016/j.jacc.2018.03.515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。